Nilotinib (AMN-107)

Modify Date: 2024-01-02 07:35:16

Nilotinib (AMN-107) structure	Common Name	Nilotinib (AMN-107)
	CAS Number	641571-10-0	Molecular Weight	529.516
	Density	1.4±0.1 g/cm3	Boiling Point	N/A
	Molecular Formula	C₂₈H₂₂F₃N₇O	Melting Point	N/A
	MSDS	N/A	Flash Point	N/A

Use of Nilotinib (AMN-107)

Nilotinib is an orally available Bcr-Abl tyrosine kinase inhibitor with antineoplastic activity.

Name	nilotinib
Synonym	More Synonyms

Description	Nilotinib is an orally available Bcr-Abl tyrosine kinase inhibitor with antineoplastic activity.
Related Catalog	Signaling Pathways >> Autophagy >> Autophagy Signaling Pathways >> Protein Tyrosine Kinase/RTK >> Bcr-Abl Research Areas >> Cancer
Target	Bcr-Abl[1]
In Vitro	The novel, selective Abl inhibitor, Nilotinib (AMN107), is designed to interact with the ATP-binding site of BCR-ABL with a higher affinity than Imatinib. In addition to being significantly more potent compared with Imatinib (IC50<30 nM), Nilotinib also maintains activity against most of the BCR-ABL point mutants that confer Imatinib resistance[1]. Nilotinib demonstrates significant antitumor efficacy against GIST xenograft lines and Imatinib-resistant GIST cell lines. The parent cell lines GK1C and GK3C show Imatinib sensitivity with IC50 of 4.59±0.97 µM and 11.15±1.48 µM, respectively. The Imatinib-resistant cell lines GK1C-IR and GK3C-IR show Imatinib resistance with IC50 values of 11.74±0.17 µM (P<0.001) and 41.37±1.07 µM (P<0.001), respectively[2].
In Vivo	The percentage of tumor growth inhibition (TGI) is 83.8% for Imatinib and 69.6% for Nilotinib in the GK1X xenograft line (n.s.). In the GK2X xenograft line, TGI is 83.0% for Imatinib and 85.3% for Nilotinib (n.s.). Additionally, the GK3X xenograft line TGI is 31.1% for Imatinib and 47.5% for Nilotinib (n.s.). These results suggest that, except for the GK1X xenograft line, Nilotinib shows equivalent or higher antitumor effects than Imatinib[2]. Nilotinib has a significant healing effect on the macroscopic and microscopic pathologic scores and ensures considerable mucosal healing in the indomethacin-induced enterocolitis rat model. While Nilotinib decreased the PDGFR α and β levels and apoptotic scores in the colon, it did not have a significant effect on the weight and TNF-α levels. Further experimental investigations could provide more definitive evidence for humans[3].
Cell Assay	The human GIST cell lines GK1C and GK3C, and the Imatinib-resistant cell lines GK1C-IR and GK3C-IR are plated in 96-well microplates and cultured for 12 h before exposure to Imatinib (1-100 µM) or Nilotinib (1-100 µM) for 72 h. The cells are quantified by the WST-8 assay. The optical density (OD) is determined with Sunrise rainbow. The rate of inhibition is calculated as follows: % of inhibition=(OD of treated group-blank)/(OD of control group-blank)×100%. The concentration of tested drugs resulting in 50% growth inhibition (IC50) is calculated[2].
Animal Admin	Mice[2] The GIST xenograft lines GK1X, GK2X and GK3X in nude mice are used. These xenograft lines are maintained by continual passage in BALB/cSLc-nu/nu mice. Mice bearing GK1X, GK2X and GK3X tumors (6-8 mice per group) are treated daily with vehicle or 40 mg/kg Imatinib or Nilotinib for 4 weeks. Tumor volume (TV) is determined from caliper measurements of tumor length (L) and width (w) according to the formula LW2/2. TV is determined every two to three days and on the day of evaluation. Mice are sacrificed and the percentage of tumor growth inhibition (TGI) is calculated as follows: TGI (%)=[1-(mean of treatment group tumor volume on evaluation day-mean of treatment group tumor volume on day 1)/(mean of control group tumor volume on evaluation day-mean of control group tumor volume on day 1)]×100. Rats[3] Female Wistar albino rats, weighing 226-243 g (mean weight, 241.09 g), for use in this study. Nilotinib, administered 20 mg/kg/d in two divided doses, is administered to the Nilotinib group of rats (n=7) for 13 d through an orogastric tube, beginning on the same day as indomethacin administration. Blood and tissue samples for pathological examination are obtained from all rats under ether anesthesia at the end of the 13-d period. All animals are then sacrificed by decapitation.
References	[1]. Weisberg E, et al. Beneficial effects of combining nilotinib and imatinib in preclinical models of BCR-ABL+ leukemias. Blood. 2007 Mar 1;109(5):2112-20. [2]. Sako H, et al. Antitumor effect of the tyrosine kinase inhibitor Nilotinib on gastrointestinal stromal tumor (GIST) and Imatinib-resistant GIST cells. PLoS One. 2014 Sep 15;9(9):e107613. [3]. Dervis Hakim G, et al. Mucosal healing effect of nilotinib in indomethacin-induced enterocolitis: A rat model. World J Gastroenterol. 2015 Nov 28;21(44):12576-85. [4]. Fujita KI, et al. Involvement of the Transporters P-Glycoprotein and Breast Cancer Resistance Protein in Dermal Distribution of the Multikinase Inhibitor Regorafenib and Its Active Metabolites. J Pharm Sci. 2017 Sep;106(9):2632-2641. [5]. Meirson T, et al. Targeting invadopodia-mediated breast cancer metastasis by using ABL kinase inhibitors. Oncotarget. 2018 Apr 24;9(31):22158-22183.

Density	1.4±0.1 g/cm3
Molecular Formula	C₂₈H₂₂F₃N₇O
Molecular Weight	529.516
Exact Mass	529.183777
PSA	97.62000
LogP	5.15
Index of Refraction	1.650
Storage condition	-20°C Freezer

RIDADR	2206
Packaging Group	III
Hazard Class	6.1(b)

Precursor 9
CAS#:641571-11-1 3-(4-Methyl-1H-... CAS#:917392-54-2 methyl 4-methyl... CAS#:1692-25-7 3-Pyridylboroni... CAS#:1345336-53-9 3-(diaminomethy...
CAS#:55314-16-4 1-(3-Pyridyl)-3... CAS#:926922-18-1 N-(3-(TRIFLUORO... CAS#:66521-66-2 4-pyridin-3-ylp... CAS#:822-36-6 4-Methylimidazole
CAS#:1205540-16-4 N-(3-bromo-5-(t...
DownStream 1
CAS#:923288-90-8 Nilotinib monoh...

Nilotinib

Nilotinib (AMN-107)

4-Methyl-N-[3-(4-methyl-1H-imidazol-1-yl)-5-(trifluoromethyl)phenyl]-3-{[4-(3-pyridinyl)-2-pyrimidinyl]amino}benzamide

its intermediates

tasigna

Nilotinib,AMN107,Tasigna

AMN 107

4-Methyl-N-[3-(4-methyl-1H-imidazol-1-yl)-5-(trifluormethyl)phenyl]-3-{[4-(pyridin-3-yl)pyrimidin-2-yl]amino}benzolcarboxamid

4-Methyl-N-[3-(4-methyl-1H-imidazol-1-yl)-5-(trifluoromethyl)phenyl]-3-{[4-(pyridin-3-yl)pyrimidin-2-yl]amino}benzamide

Benzamide, 4-methyl-N-[3-(4-methyl-1H-imidazol-1-yl)-5-(trifluoromethyl)phenyl]-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-

4-Methyl-N-(3-(4-methyl-1H-imidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-(4-(pyridin-3-yl)pyrimidin-2-ylamino)benzamide

Nilotinib for research

Nilotinib(AMN 107)

4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide

Shanghai Jizhi Biochemical Technology Co., Ltd
China
Product Name: Nilotinib (AMN-107)
Price: ￥478.0/500mg ￥168.0/100mg
Purity: 98.0%
Stocking Period: 2 Day
Contact: Liu jia

DC Chemicals Limited
China
Product Name: Nilotinib
Price: $100.0/100mg $200.0/250mg $500.0/1g
Purity: 98.0%
Stocking Period: 3 Day
Contact: Tony Cao

Henan Tianfu Chemical Co., Ltd.
China
Product Name: Nilotinib & its intermediates
Price: $Inquiry/1kg $Inquiry/25kg $Inquiry/1000kg $Inquiry/10ton
Purity: 99.0%
Stocking Period: Inquiry
Contact: Anson

Get all suppliers and price by the below link:

Nilotinib (AMN-107) suppliers

Price: $66/10mM*1mLinDMSO

Reference only. check more Nilotinib (AMN-107) price